Comparative Evaluation of FUNGITEST and Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Candida Species and Cryptococcus neoformans
- 1 April 1998
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 36 (4) , 926-930
- https://doi.org/10.1128/jcm.36.4.926-930.1998
Abstract
The FUNGITEST method (Sanofi Diagnostics Pasteur, Paris, France) is a microplate-based procedure for the breakpoint testing of six antifungal agents (amphotericin B, flucytosine, fluconazole, itraconazole, ketoconazole, and miconazole). We compared the FUNGITEST method with a broth microdilution test, performed according to National Committee for Clinical Laboratory Standards document M27-A guidelines, for determining the in vitro susceptibilities of 180 isolates of Candida spp. (50 C. albicans, 50 C. glabrata, 10 C. kefyr, 20 C. krusei, 10 C. lusitaniae, 20 C. parapsilosis, and 20 C. tropicalis isolates) and 20 isolates of Cryptococcus neoformans. Overall, there was 100% agreement between the methods for amphotericin B, 95% agreement for flucytosine, 84% agreement for miconazole, 83% agreement for itraconazole, 77% agreement for ketoconazole, and 76% agreement for fluconazole. The overall agreement between the methods exceeded 80% for all species tested with the exception of C. glabrata (71% agreement). The poorest agreement between the results for individual agents was seen with C. glabrata (38% for fluconazole, 44% for ketoconazole, and 56% for itraconazole) and C. tropicalis (50% for miconazole). The FUNGITEST method misclassified as susceptible 2 of 12 (16.6%) fluconazole-resistant isolates, 2 of 10 (20%) itraconazole-resistant isolates, and 4 of 8 (50%) ketoconazole-resistant isolates of several Candida spp. Further development of the FUNGITEST procedure will be required before it can be recommended as an alternative method for the susceptibility testing of Candida spp. or C. neoformans.Keywords
This publication has 17 references indexed in Scilit:
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin BJournal of Clinical Microbiology, 1997
- Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapyJournal of Clinical Microbiology, 1996
- Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patientsJournal of Antimicrobial Chemotherapy, 1995
- Detection of amphotericin B-resistant Candida isolates in a broth-based systemAntimicrobial Agents and Chemotherapy, 1995
- Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study GroupAntimicrobial Agents and Chemotherapy, 1995
- Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a HumanAntimicrobial Agents and Chemotherapy, 1979
- Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function.1978
- Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte functionThe Lancet Healthy Longevity, 1978